Home / Conferences


13th Legal Affairs Conference

13th Legal Affairs Conference
22─23 March 2017
Grange Tower Bridge Hotel
London, UK

15th Biosimilar Medicines Conference

15th Biosimilar Medicines Conference
23–24 March 2017
Grange Tower Bridge Hotel
London, UK

SMi 9th Adaptive Designs in Clinical Trials 2017

SMi 9th Adaptive Designs in Clinical Trials
3–4 April 2017
Copthorne Tara Hotel
London, UK

World Biosimilar Congress USA 2017

World Biosimilar Congress USA
23–24 May 2017
Hilton San Diego Resort and Spa 
San Diego, CA, USA

Joint 23rd Medicines for Europe and 20th IGBA Annual Conference

Joint 23rd Medicines for Europe and 20th IGBA Annual Conference
14–16 June 2017
Epic Sana Lisboa Hotel
Lisbon, Portugal

European Pharmacopoeia prepares for the future through exchange with stakeholders

To mark the publication of the 9th edition of the European Pharmacopoeia (Ph. Eur.), the EDQM (European Directorate for the Quality of Medicines) organized a large international conference in Tallinn, Estonia, which brought together representatives of European and international regulatory authorities, the World Health Organization (WHO), pharmacopoeias from different continents as well as industry and associations from Europe and beyond. Participants came from 41 different countries, including Brazil, Canada, India, Japan, South Africa, Taiwan and USA.

Extrapolation key issue at European biosimilars conference

The European Generic medicines Association (EGA) held its 13th EGA-European Biosimilars Group Conference in London on 23–24 April 2015.

French generics association promotes biosimilars

French generics association GEMME held its first symposium on the challenges and opportunities associated with biosimilars in France on 3 October 2014.

Topics presented at the 16th IGPA conference on generics

Topics presented at the 16th Annual IGPA Conference, held in Brussels, Belgium, 9–11 December 2013, showed that despite differences in the pharmaceutical market in different countries most appreciate the value of generics. In most cases this is driven by cost reduction.

EGA pushes for increased focus on generics and biosimilars

EGA President Ms Gudbjorg Edda Eggertsdottir, speaking at the European Generic medicines Association’s (EGA’s) conferences in London, UK (11th EGA International Symposium on Biosimilar Medicines) and in Athens, Greece (19th EGA Annual Conference); stressed the importance of keeping generics and biosimilars manufacturers within Europe, thus ensuring that high quality manufacturing jobs and know-how remains in Europe. This would benefit society and patients and increase the competitiveness and innovative capacity of the pharmaceutical industry in Europe.